Abstract:BACKGROUND-AIMPharmacogenetics is a discipline oriented to the study of the genetic basis of interindividual differences in the response to drugs, both at the level of efficacy and safety.One of the most widely used applications of Pharmacogenetics in clinical practice is the genetic test for HLA-B*5701 in patients who are going to start treatment with abacavir, due to its relationship with the hypersensitivity reaction it produces.Other adverse reactions of this type are: Relationship HLA-B15.02 with Steven-Johnson Syndrome and toxic epidermal necrolysis by carbamazepine, relationship HLA-B58.01 with Hypersensitivity Syndrome, Steven Johnson Syndrome and toxic epidermal necrolysis by allopurinol, relationship HLA-B35 with skin eruption by nevirapine and relationship HLA-B13.01 with hypersensitivity reaction induced by dapsone (DIHR).The objective of the study is to determine the prevalence of the HLA-B57.01 allele and the HLA-B35.05,HLA-B58.01,HLA-B15.02 and HLA-B13.01 alleles associated with adverse drug reactions in our healthcare area. METHODSDescriptive observational study of patients with HIV diagnosis, with request for genotyping HLA-B57.01 in our hospital area between July 2016 and September 2019 They were a total of 613 patients.Maxwell® 16 System, Blood DNA Purification System, was used to isolate the DNA in an automated way, which was later amplified by PCR.A strip probe assay, INNO-LiPAHLA-B Update Plus, was then used to determine the molecular typing of human leukocyte antigen (HLA) B alleles.The results were analyzed using Excel. RESULTSTo determine the prevalence of HLA-B alleles, an Excel database was created with a total of 613 samples.A prevalence of 3.75% was found for the HLA B57.01 allele.The prevalences of the other alleles with their respective confidence intervals (IC95%) and number of patients are detailed below: HLA-B 57.01 3,75% (2,51-5,57) 23 patients, HLA-B 58 0,82% (0,35-1,89) 5 patients, HLA-B35 9,79% (7,68-12,40) 60 patients, HLA-B15 1,14% (0,55-2,34) 7 patients and HLA-B13 1,63% (0,89-2,98) 10 patients. CONCLUSIONSThe calculated prevalences are lower than those described by other studies, such as the PREDICT-1 study with the participation of 15 European countries.We also found a high prevalence of the HLA-B35 allele, associated with adverse reactions to Nevirapine, more particularly the skin eruption induced by this second line antiretroviral in Spain.This high prevalence of HLA-B alleles associated with drug intolerance in our HIV population suggests that the determination of these alleles may be of great importance and utility in routine clinical practice in the at-risk population.

Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles

A Case of Drug Hypersensitivity Syndrome Caused by Allopurinol

Hla-B*58:01 Allele is Associated with Augmented Risk for Both Mild and Severe Cutaneous Adverse Reactions Induced by Allopurinol in Han Chinese

Allopurinol-induced severe cutaneous adverse reactions in Vietnamese: the role of HLA alleles and other risk factors

Study on the relationship between HLA-B * 5801 and severe cutaneous adverse reactions caused by allopurinol

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin

Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population–based cohort study

Human Leukocyte Antigen B14:01 and B35:01 Are Associated With Trimethoprim‐Sulfamethoxazole Induced Liver Injury

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study

Allopurinol hypersensitivity syndrome and acute myocardial infarction--two case reports

DNA methylation of ITGB2 contributes to allopurinol hypersensitivity

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions

HLA-B*5801 testing: Is it time to consider mandatory testing prior to prescribing allopurinol in Singapore?

Toxicology, Including Therapeutic Drug Monitoring

HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia

ALLOPURINOL INDUCED ADVERSE DRUG REACTIONS: CASE SERIES

HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease

Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study

Fixed Drug Eruption in a Patient of HLA-B*58:01 Negative after Allopurinol Administration: A Case Report

Detection of HLA-B*58:01 with TaqMan Assay and Its Association with Allopurinol-Induced Scadr

The Association Between HLA-DQB1 Polymorphism and Antituberculosis Drug-Induced Liver Injury: a Case-Control Study.